SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Mac who wrote (657)7/16/1998 4:53:00 PM
From: admr  Read Replies (1) of 1754
 
I don't know that percentage. What I do know is that the use of the excimer laser in hyperopia is very invasive and has had lots of complications. Snrs just contacted with Omnicom for marketing.
It seems to me with the visx stock close to 70 they should buy snrs
and lock up the market for hyperopia and presbyopia. A surgeon friend
of mine with experience with both lasers says that you have to be out of your mind to use the excimer laser when the LTK process with the Holmium laser is so much easier, cheaper, less invasive with much
better results. Snrs I.m told expects to be listed on the Nasdaq
soon. The Snrs laser I'm told is about 200,000 dollars also much
cheaper for the individual ophthalmogist so they might get better
market penetration. Lots of luck any other thought would be appreciated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News